Foghorn Therapeutics Inc. (FHTX) Downgraded to Neutral by BTIG

Market Context

Foghorn Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $2.02 with a market capitalization of $252.8M. The stock has declined 55.1% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow BTIG's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Foghorn Therapeutics Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 02, 2026	BTIG	Neutral	N/A
Oct 02, 2026	Wedbush	Neutral	N/A
Oct 02, 2026	TD Cowen	Hold	N/A
Oct 02, 2026	Guggenheim	Buy	N/A
Oct 02, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View FHTX Stock Page